$0.61
+0.00 (+0.51%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MBRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLNCT06788756Part A -Determination of Optimal Dosage RegimenRandomized · Triple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection. | Acute Myeloid Leukaemia (AML) | 312 | Aug 2029 | ≤ 1,108 d | 2026-08-05 |
| Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)NCT05319587Evaluate the safety and identify the MTD/RP2D of L-Annamycin in combination with a standard regimen of cytarabine (Ara-C, cytosine arabinoside)Open-label · Treatment | Phase 1/2 | Completed | Drug: Liposomal Annamycin, Cytarabine | Leukemia, Myeloid, Acute | 22 | 2023-08-02actual | — | 2025-09-30 |
| Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy VolunteersNCT05195723Safety in Single Ascending Dose (SAD)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: WP1122, Placebo | Healthy Volunteer | 48 | 2022-10-24actual | — | 2023-02-27 |
| Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary MetastasesNCT04887298Dose Limiting ToxicityOpen-label · Treatment | Phase 1/2 | Completed | Drug: Liposomal Annamycin (L-Annamycin) | Sarcoma,Soft Tissue, Pulmonary Metastasis | 36 | 2022-09-29actual | — | 2024-10-24 |
| Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)NCT03388749Evaluation of safety and identification of the MTD/RP2D for L-AnnamycinOpen-label · Treatment | Phase 1/2 | Completed | Drug: Liposomal Annamycin | Leukemia, Myeloid, Acute | 20 | 2022-02-08actual | — | 2023-01-20 |
| Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)NCT03315039results2022-02-23Dose-limiting ToxicityOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Liposomal Annamycin | Leukemia, Myeloid, Acute | 7 | 2020-01-14actual | — | 2022-03-10 |
| Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)NCT04702503Evaluation of the safety profile of WP1220 applied topically (adverse events)Open-label · Treatment | Phase 1 | Completed | Drug: WP1220 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | 5 | 2019-11-15actual | — | 2021-01-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19